DEA Proposes Overhaul of Controlled Substance Manufacturing and Procurement Quota Rules

What this means for your practice

While this proposed rule targets DEA-registered manufacturers — not individual prescribers or telehealth platforms — it carries meaningful downstream implications for healthcare operators who rely on Schedule II controlled substances. Tighter quota tracking and improved supply chain visibility could affect drug availability for high-demand medications, including stimulants, opioids, and other Schedule II drugs that telehealth prescribers and their patients depend on. Operators experiencing controlled substance shortages — a recurring challenge in recent years — should monitor this rulemaking closely, as the DEA's stated goal is to use more granular quota data to prevent drug shortages more precisely. Telehealth brands, medspas, and other practices that prescribe controlled substances should consider submitting public comments if supply disruptions have impacted their patient populations, and should ensure their compliance teams are tracking how final quota rules may affect formulary availability.

DEA Proposes Major Restructuring of Controlled Substance Quota Regulations

The Drug Enforcement Administration (DEA) has published a Notice of Proposed Rulemaking (NPRM) in the Federal Register proposing significant revisions to the regulations that govern how manufacturers apply for and receive quotas to produce Schedule I and II controlled substances, as well as the three List I chemicals: ephedrine, pseudoephedrine, and phenylpropanolamine.

The proposed rule, docketed as DEA-1278 (RIN 1117-AB86) and published on May 20, 2026, proposes amendments to 21 CFR Parts 1303 and 1315. The comment period closes July 20, 2026.

What Are Manufacturing and Procurement Quotas?

Under the Controlled Substances Act (CSA), the DEA Administrator is required to establish an Aggregate Production Quota (APQ) for each basic class of controlled substance listed in Schedules I and II, as well as an Assessment of Annual Needs (AAN) for the three List I chemicals. These figures represent the total quantity that may be manufactured in the United States each calendar year to meet estimated medical, scientific, research, and industrial needs — including lawful export.

Individual DEA-registered manufacturers must then apply for their share of that quota. The quota system is one of the CSA's primary tools for controlling the volume of controlled substances entering the legal supply chain.

What Is the DEA Proposing to Change?

The proposed rule has several distinct objectives:

1. Restructuring for Clarity and Consistency The DEA proposes to reorganize its manufacturing and procurement quota regulations to make them clearer and more internally consistent. This is described as a structural improvement, not a fundamental policy shift — but it signals the agency's intent to modernize how it administers quota management.

2. Clarifying Domestic vs. Export Quota Subcategories The proposed rule would clarify which use-specific quota subcategories apply to controlled substances intended for domestic sale versus those intended for export. This distinction matters for manufacturers operating across both markets and helps DEA track supply flows with greater precision.

3. Revising the Quota Application Process DEA proposes revisions to the actual application forms and processes for individual manufacturing and procurement quotas. The goal is to collect more detailed information from applicants so the agency can make more targeted and precise decisions about production levels.

4. Preventing Drug Shortages A central stated rationale for this rulemaking is to give DEA greater visibility into the controlled substance supply chain. According to the NPRM, the additional data collected through revised applications will allow the agency to "react more precisely in preventing drug shortages" — a direct acknowledgment that current quota mechanisms have contributed to supply disruptions.

5. Non-Substantive Updates The rule also includes revisions to use gender-neutral language and other non-substantive clarifications.

Why This Matters Beyond Manufacturers

While the immediate regulatory audience is DEA-registered manufacturers — not prescribers, telehealth platforms, or clinical practices — the downstream effects of quota policy are felt throughout the healthcare system.

In recent years, shortages of Schedule II stimulants (such as those used to treat ADHD) have been directly linked to quota constraints and supply chain bottlenecks. Telehealth platforms that expanded access to these medications found their patients facing pharmacy-level unavailability despite valid prescriptions.

The DEA's explicit goal of using more granular data to prevent shortages suggests the agency recognizes this systemic problem. If the proposed changes enable more responsive quota adjustments, the practical effect for telehealth operators and their patients could be meaningfully positive over time.

Who Should Pay Attention

• Telehealth platforms prescribing Schedule II controlled substances (stimulants, opioids, certain weight-loss medications)
• Medspas and aesthetic practices using Schedule II compounds
• Behavioral health and psychiatric telehealth providers
• Dental and pain management practices reliant on Schedule II analgesics
• Compliance officers tracking DEA rulemaking that affects formulary access
• Any operator whose patient population has experienced controlled substance shortages

How to Participate in the Rulemaking

The DEA is accepting public comments through July 20, 2026. Healthcare operators, telehealth companies, and professional associations with firsthand experience of supply disruptions caused by quota limitations have a meaningful opportunity to contribute to the administrative record.

Comments may be submitted: - Electronically at https://www.regulations.gov (search Docket No. DEA-1278) - By mail to: Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152

> Important: Comments are public records and will not be redacted unless you follow DEA's dual-submission process for confidential business information. Do not include sensitive personally identifiable information in standard submissions.

For questions, the DEA contact is: Heather Achbach, Regulatory Drafting & Policy Section, Diversion Control Division — (571) 776-3882.

Key Takeaways for Healthcare Operators

• This is a proposed rule, not a final rule — the regulatory process is still open
• The rule targets manufacturers, but affects supply availability for all prescribers and dispensers
• DEA's stated goal of preventing drug shortages through better data is a direct response to documented supply chain failures
• Operators who have experienced controlled substance shortages should consider submitting comments documenting the patient impact
• Final rules amending 21 CFR Parts 1303 and 1315 should be tracked by compliance teams at any organization dependent on Schedule I or II controlled substance access

Source: DEA — Proposed Rule: Revision of Applications for Manufacturing and Procurement Quotas · 2026-05-20